79 related articles for article (PubMed ID: 26817317)
1. [Treatment costs of malignant cervical cancer in Poland in 2011-2012--the case of Silesian Voivodeship].
Holecki T; Sobczyk K; Nawrocki S; Woźniak-Holecka J; Skrzypek M; Bocionek A
Ginekol Pol; 2015 Nov; 86(11):849-55. PubMed ID: 26817317
[TBL] [Abstract][Full Text] [Related]
2. [Costs of population cervical cancer screening program in Poland between 2007-2009].
Spaczyński M; Karowicz-Bilinska A; Kedzia W; Molińska-Glura M; Seroczyński P; Januszek-Michalecka L; Rokita W; Nowak-Markwitz E
Ginekol Pol; 2010 Oct; 81(10):750-6. PubMed ID: 21117303
[TBL] [Abstract][Full Text] [Related]
3. [Estimated cost of managing invasive cervical cancer in Tunisia].
Ben Gobrane H; Aounallah-Skhiri H; Oueslati F; Frikha H; Achour N; Hsairi M
Sante Publique; 2009; 21(6):561-9. PubMed ID: 20429226
[TBL] [Abstract][Full Text] [Related]
4. Production lost due to cervical cancer in Poland in 2012.
Dubas-Jakóbczyk K; Kocot E; Seweryn M; Koperny M
Med Pr; 2016; 67(3):289-99. PubMed ID: 27364103
[TBL] [Abstract][Full Text] [Related]
5. Direct costs of cervical cancer management in Morocco.
Berraho M; Najdi A; Mathoulin-Pelissier S; Salamon R; Nejjari C
Asian Pac J Cancer Prev; 2012; 13(7):3159-63. PubMed ID: 22994727
[TBL] [Abstract][Full Text] [Related]
6. ["Cost-effectiveness" of cervical screening].
Kostova P
Akush Ginekol (Sofiia); 2007; 46(6):32-4. PubMed ID: 17974169
[TBL] [Abstract][Full Text] [Related]
7. [Epidemiology of asthma in adults living in the Silesian voivodeship according to secondary epidemiological data].
Niewiadomska E; Kowalska M
Med Pr; 2017 Jun; 68(4):479-489. PubMed ID: 28592907
[TBL] [Abstract][Full Text] [Related]
8. Annual national direct and indirect cost estimates of the prevention and treatment of cervical cancer in Brazil.
Novaes HM; Itria A; Silva GA; Sartori AM; Rama CH; Soárez PC
Clinics (Sao Paulo); 2015 Apr; 70(4):289-95. PubMed ID: 26017797
[TBL] [Abstract][Full Text] [Related]
9. Cervical, Vaginal, and Vulvar Cancer Costs Incurred by the Medicaid Program in Publicly Insured Patients in Texas.
Fu S; Fokom Domgue J; Chan W; Zhao B; Ramondetta LM; Lairson DR
J Low Genit Tract Dis; 2019 Apr; 23(2):102-109. PubMed ID: 30907776
[TBL] [Abstract][Full Text] [Related]
10. Incidence and economic burden of sarcoidosis in years 2011-2015 in Silesian voivodeship, Poland.
Niewiadomska E; Kowalska M; Skrzypek M; Bocionek A; Czech E
Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(1):43-52. PubMed ID: 33093768
[TBL] [Abstract][Full Text] [Related]
11. [Cost effectiveness analysis of screening strategies for cervical cancer in Tunisia].
Lazaar HB; Aounallah-Skhiri H; Oueslati F; Frikha H; Achour N; Hsairi M
East Mediterr Health J; 2010 Jun; 16(6):602-8. PubMed ID: 20799586
[TBL] [Abstract][Full Text] [Related]
12. [Estimation of health-care costs for cervical uterine neoplasm].
Sánchez-Román FR; de Jesús Carlos-Rivera F; Guzmán-Caniupan JA; Escudero-de Los Ríos P; Juárez-Pérez CA; Aguilar-Madrid G
Rev Med Inst Mex Seguro Soc; 2012; 50(1):99-106. PubMed ID: 22768826
[TBL] [Abstract][Full Text] [Related]
13. Modeling cost-effectiveness of cervical cancer screening in Hungary.
Vokó Z; Nagyjánosi L; Margitai B; Kövi R; Tóth Z; László D; Kaló Z
Value Health; 2012 Jan; 15(1):39-45. PubMed ID: 22264970
[TBL] [Abstract][Full Text] [Related]
14. [Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007--results of multicenter Polish study].
Jahnz-Rózyk K; Targowski T; From S
Pol Merkur Lekarski; 2009 Mar; 26(153):208-14. PubMed ID: 19388534
[TBL] [Abstract][Full Text] [Related]
15. Management of women with abnormal cervical cytology: treatment patterns and associated costs in England and Wales.
Martin-Hirsch P; Rash B; Martin A; Standaert B
BJOG; 2007 Apr; 114(4):408-15. PubMed ID: 17378815
[TBL] [Abstract][Full Text] [Related]
16. [Awareness of cervical cancer prevention among patients of gynecological outpatient clinic].
Ulman-Włodarz I; Nowosielski K; Romanik M; Pozowski J; Jurek M
Ginekol Pol; 2011 Jan; 82(1):22-5. PubMed ID: 21473052
[TBL] [Abstract][Full Text] [Related]
17. Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.
Östensson E; Fröberg M; Leval A; Hellström AC; Bäcklund M; Zethraeus N; Andersson S
PLoS One; 2015; 10(9):e0139062. PubMed ID: 26398189
[TBL] [Abstract][Full Text] [Related]
18. Determining costs of health care services for cost-effectiveness analyses: the case of cervical cancer prevention and treatment.
Helms LJ; Melnikow J
Med Care; 1999 Jul; 37(7):652-61. PubMed ID: 10424636
[TBL] [Abstract][Full Text] [Related]
19. The direct and indirect costs of epilepsy in Poland estimates for 2014-2016 years.
Mela A; Staniszewska A; Wrona W; Poniatowski ŁA; Jaroszyński J; Niewada M
Expert Rev Pharmacoecon Outcomes Res; 2019 Jun; 19(3):353-362. PubMed ID: 30293466
[TBL] [Abstract][Full Text] [Related]
20. An alternative cost effectiveness analysis of ThinPrep in the Australian setting.
Neville AM; Quinn MA
Aust N Z J Obstet Gynaecol; 2005 Aug; 45(4):289-94. PubMed ID: 16029294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
